Aygen, BilgehanDemirtürk, NeşeYıldız, OrhanÇelen, Mustafa KemalÇelik, İlhamiBarut, ŞenerUral, OnurBatırel, AyşeŞimşek, FundaAşan, AliErsöz, GüldenTürker, NesrinBilgin, HüseyinKınıklı, SamiKarakeçili, FarukZararsız, Gökmen2024-01-102024-01-102020-04Aygen, B. vd. (2020). "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience". Turkish Journal of Gastroenterology, 31(4), 305-317.https://turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotype-1-or-4-infection-the-turkey-experience-experience-136659https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236650/https://hdl.handle.net/11452/38946Bu çalışma, 15-16, Mart 2019 tarihlerinde İstanbul[Türkiye]’de düzenlenen AASLD - TASL Connect Regional Meeting Kongresi‘nde bildiri olarak sunulmuştur.Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r +/- DSV +/- RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed.Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naive. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%.Conclusion: The present real-life data of Turkey for the OBV/PTV/r +/- DSV +/- RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile.eninfo:eu-repo/semantics/openAccessGastroenterology & hepatologyChronic hepatitis cHcv genotypes 1 and 4OmbitasvirParitaprevirDasabuvirReal-world effectivenessSustained virological responseRitonavir plus ribavirinAntiviral therapyHcvOmbitasvirParitaprevirAbt-450/r-ombitasvirMulticenterParitaprevir/ritonavir/ombitasvirRetreatment2-NaphthylamineAdultAgedAged, 80 and overAnilidesAntiviral agentsCyclopropanesDatabasesFactualDrug therapy, combinationFemaleGenotypeHepacivirusHepatitis C, chronicHumansLactams, macrocyclicMaleMiddle agedProlineRibavirinRitonavirSulfonamidesSustained virologic responseTurkeyUracilValineYoung adultArticle0005352632000042-s2.0-8508478733430531731432412901https://doi.org/10.5152/tjg.2020.19197Gastroenterology & hepatologyDirest; BMS-790052;ABT-267DasabuvirOmbitasvir plus paritaprevir plus ritonavirRibavirinVirus rna2 naphthylamineAnilideAntivirus agentCyclopropane derivativeDasabuvirMacrocyclic lactamOmbitasvirParitaprevirProlineRibavirinRitonavirSulfonamideUracilValineAbdominal painAdultAgeAnorexiaArthralgiaArticleAstheniaChronic hepatitis cClinical outcomeClinical practiceCoughingDemographyDiarrheaDizzinessDrug efficacyDrug safetyDry skinFatigueFemaleFeverGenderHeadacheHeart palpitationHepatitis c virus genotype 4Hepatitis c virus subtype 1aHepatitis c virus subtype 1bHumanInsomniaLiver cirrhosisMajor clinical studyMaleMulticenter studyNauseaPruritusRashRetrospective studySustained virologic responseThorax painTreatment durationTreatment failureTurkey (republic)Virologic failureVirus detectionVomitingAgedChronic hepatitis cCombination drug therapyFactual databaseGeneticsGenotypeHepacivirusMiddle agedTurkey (bird)Very elderlyYoung adult2148-5607